Roche Pharmaceutical Subsidiary: Genentech Inc

Genentech, although it has been Roche Holding AG However, there are still too many legends about Big Brother in the Jianghu, so we will issue them separately.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/genentech.html

Genentech (full name: Genetic Engineering Technology) is a Biotechnology company , founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer, this event is also regarded as the starting point of biotechnology industry. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/genentech.html

As a pioneer of recombinant DNA, Boyer and his colleague Stanley Norman Cohen demonstrated the technology of using restriction enzyme as "scissors" to cut important DNA fragments and then glue them back to the plasmid vector cut by the same restriction enzyme in 1973. Although Cohen returned to academia, Swanson contacted Boyer and founded the company. Boyer cooperated with Arthur Riggs and Akichi Bankura of Beckman Research Institute to successfully express human genes in bacteria and produce somatostatin in 1977. Then David Goeddel and Dennis Kleid joined the team and successfully produced insulin together in 1978. Dr. Ellson Chen, the former chief scientist, participated in the human genome project led by the US government in the 1990s and developed the ABI 3700 full-automatic high-speed sequencer, which enabled the US government to announce the completion of the human gene sequencing sketch in 2001, which is also a promising future Gene testing Technology has laid an important foundation. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/genentech.html

As of February 2011, Genentech has more than 11000 employees. Roche, a Swiss pharmaceutical giant, completed the acquisition of Genentech on March 26, 2009 with about US $46.8 billion, and fully owns the company. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/genentech.html

Genentech Inc. Encyclopedia:

Genentech is a research oriented company based on scientific innovation. It has more than 1100 researchers, scientists, and postgraduates and conducts a wide range of scientific research and development from molecular biology, protein chemistry to bioinformatics and physiology. Scientists of Genentech in different fields now focus on the following five disease categories: oncology, immunology, tissue growth and repair, neuroscience and infectious diseases. The recent talent recruitment and acquisition case of Genentech shows that its development tends to microbiology, medical imaging and neuroscience. Genentech's research equipment is only set up in the South San Francisco Park, and is only used by a small development team in Oceanside. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/genentech.html

Genentech's head office is located in South San Francisco, with factories in Wakaville and Oceanside. On March 17, 2006, Genentech announced that it would build a new fill/finish factory and shipping center in Hillsborough (near Portland), Oregon, and planned to start in 2010. In December 2006, Genentech sold its equipment in Porri ñ o, Spain to Lonza and obtained the exclusive right to purchase the mammalian cell culture factory under construction in Lonza, Singapore. In June 2007, Genentech launched the development and construction of its Escherichia coli manufacturing plant in Singapore, aiming at the global manufacturing of LUCENTIS (Lenimab injection) API substances, and is expected to be certified in early 2010. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/genentech.html

In 1999, Genentech agreed to pay the University of California, San Francisco, $200 million to end a nine year patent dispute. In 1990, the University of California, San Francisco, accused Genentech of stealing a patented technology in 1982 and claimed 400 million dollars. Genentech claims that the development of growth hormone protropin (which can treat dwarfism) has nothing to do with the University of California, San Francisco. The judge ruled in July of the previous year that the enlarged patent was valid, but it was impossible to judge whether the development of Ptrotropin used the research of the University of California, San Francisco. Protopin is the first product of Genentech, and its operating income of 2 billion dollars is an important factor that makes Genentech become an industry leader. The use of $200 million is: $30 million for the University of California General Fund, $85 million for three inventors and two collaborators, $50 million for a new teaching and research district, and $35 million for research. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/genentech.html

Genentech Inc. Product Encyclopedia

• 1982 - United States food The Drug Administration (FDA) approved the synthesis of "human" insulin. This development is due to the completion of the approval process for this product by Eli Lilly, the partner of insulin manufacturing. This product (Humulin) is authorized to be manufactured by Lilly, which is the first approved genetically modified medical product.
• 1985 - Propropin (somatrem) - Secondary growth hormone for children with growth hormone deficiency (discontinued in 2004).
• 1987 - Activase, a recombinant tissue type plasminogen activator (tPa), can dissolve blood clots in patients with severe myocardial infarction. It is also used to treat non hemorrhagic strokes.
• 1990 - Actimmune (interferon gamma 1b) - for the treatment of chronic granulomatosis (licensed to Intermune).
• 1993 - Nutropin (recombinant growth hormone) - for the treatment of chronic renal insufficiency before kidney transplantation.
• 1993 - Pumozyme - Respiratory therapy against cystic fibrosis in young children or young adults - recombinant DNAse.
• 1997 - Rituxan (rituxan) - for the treatment of certain kinds of non Hodgkins limphomas. It was also approved for the treatment of rheumatoid arthritis in 2006.
• 1998 - Herceptin (trastuzumab) - for metastatic breast cancer patients who overexpress HER2 gene. Recently, it has also been approved for adjuvant therapy of breast cancer. The FDA also recently approved trastuzumab for metastatic gastric cancer with HER2 receptor positive.
• 2000 - TNKase (tenecteplase) - thrombolytic drug for severe myocardial infarction.
• 2003 - Xolair (omalizumab) - for patients with moderate to severe asthma.
• 2003 - Raptiva (Fadrizumab) - an antibody designed to block psoriasis caused by activation and reactivation of T cells. Developed with XOMA. Due to the report that Raptiva caused progressive multifocal leukoencephalon, Genentech withdrew this product from the US market in 2009.
• 2004 - Avastin - anti VEGF monoclonal antibody for the treatment of metastatic cancer located in the colon or rectum. It was also approved for locally spread, recurrent and metastatic non-small cell lung cancer in 2006. In 2008, the combination therapy of Avastin and chemotherapy was also approved for the treatment of invasive HER2-negative breast cancer without treatment before. In 2009, Avastin was approved for the fifth time for the treatment of glioblastoma and the sixth time for the treatment of metastatic renal cell carcinoma.
• 2004 - Tarceva (erlotinib) - for sentence spread or metastatic non-small cell lung cancer and pancreatic cancer.
• 2006 - Lucentis (Lannimab injection) - The U.S. Food and Drug Administration (FDA) has approved LECENTIS for the treatment of neovascular age-related macular disease. FDA's approval went through six months of priority review. Genentech was approved to ship on June 30, 2006.
• On January 8, 2010, FDA approved Actemra (tocilizumab), which is the first monoclonal antibody approved to treat rheumatoid joints (RA) by inhibiting IL-6 receptor.
• 2012 - FDA approved the combination of PERJETA (Paretozumab), Herceptin (Trastuzumab) and docetaxel chemotherapy for the treatment of previously untreated HER2 positive metastatic breast cancer (MBC) patients.
• Ongoing work - Genentech is developing monoclonal antibodies that block DR-6 and anti N-APP as a possible delayed treatment for neuronal damage in the early stage of Alzheimer's disease. Just like any DR-6 and N-APP method to prevent Alzheimer's disease needs long-term intervention, the effective half-life of any monoclonal antibody needs a long time. Use siRNA or N-APP for DR-6 vaccine These restrictions may be circumvented.
• Official website: https://www.gene.com/